Japan Age-Related Macular Degeneration Therapeutics Market Report 2022 to 2030

Japan Age-Related Macular Degeneration Therapeutics Market Analysis

$ 3999

The Japan Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $671 Mn in 2022, and is predicted to grow at a CAGR of 9.40% from 2023 to 2030, to US $1.377 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, technological advancements, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others

ID: IN10JPPH427 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Riddhi Solanki

Buy Now

Japan Age-Related Macular Degeneration Therapeutics Market Analysis: Executive Summary

The Japan Age-Related Macular Degeneration (AMD) Therapeutics Market is at around US $0.67 Bn in 2022 and is projected to reach US $1.37 Bn in 2030, exhibiting a CAGR of 9.40% during the forecast period.

Age-related macular degeneration (AMD) is a progressive eye condition primarily impacting older individuals, potentially resulting in significant vision impairment. It affects the macula, which is responsible for central vision, making activities like reading challenging. Risk factors encompass diabetes, smoking, lifestyle changes, and others. AMD presents in two main forms: dry AMD and wet AMD. Symptoms involve distorted vision, difficulty seeing clearly, and a gradual decline in vision. Dry AMD is more prevalent but advances more slowly. On the other hand, wet AMD, though less common, is more severe and characterized by abnormal blood vessel growth beneath the macula. Treatment options include anti-VEGF therapy using medications such as Lucentis, Vabysmo, Avastin from Genentech, and Eylea from Regeneron Pharmaceuticals. Additionally, treatment may involve laser therapy and nutritional supplements like zinc and copper.

It is estimated that the prevalence of early-stage AMD is around 22.3% and approximately 10-15% of individuals aged 65 and above in Japan experience AMD. The market is therefore driven by major factors like an increase in the aging population and the subsequent increase in prevalence, evolving healthcare infrastructure, and technological advancements in the therapeutics industry. However, limited treatment options and market accessibility are a few factors that limit the market's potential.

The market is currently being dominated by Regeneron Pharmaceuticals with Eylea, which is an approved anti-VEGF drug for wet AMD. It is closely followed by Novartis, which captures a significant market share with Beovu, which is another drug in the same category.

Market Dynamics

Market Growth Drivers

Surge in the prevalence of AMD: Japan has one of the highest proportions of elderly populations globally, with more than 28% of individuals aged 65 and older. This demographic trend directly leads to a higher incidence of AMD, a significant contributor to vision impairment in older adults. Research indicates that approximately 10–15% of individuals aged 65 and above in Japan experience AMD, and wet AMD constitutes about 10–20% of these cases. The prevalence of early-stage AMD is expected to be around 22.3%, and it is steadily increasing in this demographic, which intensifies the need for efficient treatments.

Enhanced healthcare system: Japan possesses an advanced healthcare system characterized by extensive accessibility to diagnostic instruments like OTC and ophthalmologists. This setup facilitates the early identification and treatment of AMD patients, allowing market expansion

Technological advancements: Japan stands at the forefront of medical technology, driving the adoption of cutting-edge diagnostic tools and potentially paving the way for future advancements in AMD therapies, such as gene therapy and stem cell transplantations. The increasing investment in AMD therapeutics is evolving, resulting in more drugs in pipeline development entering the Japanese market.

Market Restraints

Market accessibility: Although Universal Health Insurance (UHI) encompasses a significant portion of the expenses associated with AMD treatment, certain limitations persist. Out-of-pocket costs still pose a barrier for specific patients, and the details of coverage for newer medications may take time to develop. This constraint impedes accessibility for many patients relying on the program, leading to uneven access based on their insurance status.

Treatment limitations: Currently, there are no approved medications for dry AMD, the more common form, creating a significant unmet demand. This limitation significantly impedes market expansion. Although anti-VEGF therapies demonstrate effectiveness for wet AMD, each dose of Lucentis is more than 1 million yen. This presents significant affordability challenges for both patients and the healthcare system.

Notable updates

March 2022, Chugai Pharmaceutical Co., Ltd. revealed that it has received regulatory approval today from the Ministry of Health, Labour and Welfare (MHLW) for Vabysmo® for Intravitreal Injection.

Healthcare Policies and Regulatory Landscape

Japan's healthcare policy and regulatory structure encompass various critical authorities and agencies. The primary entity responsible for healthcare regulations and licensing in Japan is the Ministry of Health, Labour, and Welfare (MHLW). The MHLW establishes the foundations and fundamental laws for the national health policy, which local governments implement. Additionally, the MHLW acts as a crucial regulatory body for the Medical and Medical Practitioners Law, overseeing various healthcare aspects, including licensing medical practitioners and regulating medical devices.

Obtaining a license for healthcare products in Japan requires adherence to regulations set by the MHLW and local governments. These entities supervise and oversee healthcare services, including the approval and monitoring of medical and healthcare products. To secure registration and marketing authorization for pharmaceuticals and medical devices, companies must receive approval from the MHRA. This process involves submitting technical and scientific data to validate the product's safety, quality, and effectiveness.

Japan's healthcare policy and regulatory framework involve numerous authorities and agencies, with the MHLW playing a pivotal role in healthcare product regulation. Both the public and private healthcare sectors in the country present diverse opportunities for companies operating within the healthcare industry.

Competitive Landscape

Key Players

Regeneron Pharmaceuticals
Novartis AG
F. Hoffman-La-Roche Ltd
Apellis Pharmaceuticals
AbbVie
Bayer
Pfizer Inc
Regenxbio Inc
Kanghong Pharma
Bausch Health Companies Inc

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Age-Related Macular Degeneration Therapeutics Market Segmentation

By Disease Type

Dry AMD
Wet AMD

By Drug

Lucentis
Eylea
Beovu

By Age Group

Less than 60
Between 60-80
More than 80

By Stage

Early AMD
Intermediate AMD
Advanced AMD
No AMD

By Distribution Channel

Hospital Pharmacy
Specialty Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.